Scarica l'app Stockscreener
244.81
1.64%
3.94
Dopo l'orario di chiusura:
244.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché RMD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$240.87
Aprire:
$241.75
Volume 24 ore:
961.23K
Relative Volume:
0.92
Capitalizzazione di mercato:
$35.73B
Reddito:
$5.26B
Utile/perdita netta:
$1.44B
Rapporto P/E:
25.05
EPS:
9.7713
Flusso di cassa netto:
$1.76B
1 W Prestazione:
+0.02%
1M Prestazione:
-2.41%
6M Prestazione:
-4.33%
1 anno Prestazione:
+7.15%
Intervallo 1D:
$240.00
$245.34
Intervallo di 1 settimana:
$240.00
$245.52
Portata 52W:
$199.92
$293.81
Resmed Inc Stock (RMD) Company Profile
Nome
Resmed Inc
Settore
Industria
Telefono
(858) 746-2400
Indirizzo
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Confronta RMD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
244.81 | 35.16B | 5.26B | 1.44B | 1.76B | 9.7713 |
|
ISRG
Intuitive Surgical Inc
|
561.98 | 200.77B | 9.61B | 2.77B | 2.27B | 7.555 |
|
BDX
Becton Dickinson Co
|
194.94 | 55.29B | 21.84B | 1.68B | 2.67B | 5.8293 |
|
ALC
Alcon Inc
|
77.60 | 38.71B | 10.19B | 1.05B | 1.38B | 2.1044 |
|
MDLN
Medline Inc
|
40.62 | 33.06B | 27.43B | 1.27B | 1.01B | 1.5829 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-16 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-09-18 | Iniziato | Citigroup | Buy |
| 2025-09-02 | Aggiornamento | CLSA | Hold → Outperform |
| 2025-07-15 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-03-19 | Iniziato | Morgan Stanley | Overweight |
| 2025-01-16 | Iniziato | Goldman | Buy |
| 2025-01-10 | Iniziato | Piper Sandler | Neutral |
| 2024-12-13 | Iniziato | Stifel | Hold |
| 2024-09-24 | Iniziato | Robert W. Baird | Outperform |
| 2024-09-18 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| 2024-09-04 | Downgrade | Needham | Buy → Hold |
| 2024-06-25 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-06-24 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-06 | Ripresa | KeyBanc Capital Markets | Overweight |
| 2023-10-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-10-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-10-09 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-09-29 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2023-09-06 | Aggiornamento | Needham | Hold → Buy |
| 2023-09-05 | Downgrade | UBS | Buy → Neutral |
| 2023-08-01 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-05-23 | Iniziato | UBS | Buy |
| 2023-04-14 | Iniziato | Mizuho | Buy |
| 2023-01-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2022-10-20 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-10-12 | Iniziato | Jefferies | Hold |
| 2022-09-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-08-15 | Downgrade | CLSA | Buy → Outperform |
| 2022-08-12 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-08-12 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-06-06 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-04-06 | Iniziato | Wolfe Research | Outperform |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-28 | Aggiornamento | RBC Capital Mkts | Underperform → Sector Perform |
| 2022-01-24 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-01-13 | Aggiornamento | CLSA | Outperform → Buy |
| 2022-01-13 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-12-21 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-12-06 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-10-22 | Aggiornamento | CLSA | Underperform → Outperform |
| 2021-08-02 | Downgrade | CLSA | Outperform → Sell |
| 2021-08-02 | Downgrade | Needham | Buy → Hold |
| 2021-07-28 | Aggiornamento | Jefferies | Underperform → Hold |
| 2021-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-07-14 | Iniziato | RBC Capital Mkts | Underperform |
| 2021-06-28 | Downgrade | Citigroup | Buy → Neutral |
| 2021-06-22 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2021-06-22 | Iniziato | Robert W. Baird | Neutral |
| 2021-06-21 | Reiterato | Needham | Buy |
| 2021-06-16 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-06-09 | Aggiornamento | CLSA | Sell → Outperform |
| 2021-05-21 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-05-11 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-04-30 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-16 | Aggiornamento | Needham | Hold → Buy |
| 2020-11-02 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-30 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-10-27 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2020-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-05-01 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-05-01 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-03 | Iniziato | CLSA | Underperform |
| 2020-01-31 | Downgrade | UBS | Buy → Neutral |
| 2020-01-10 | Iniziato | Oppenheimer | Perform |
| 2019-11-22 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2019-07-29 | Aggiornamento | UBS | Neutral → Buy |
| 2019-07-16 | Downgrade | UBS | Buy → Neutral |
| 2019-05-06 | Aggiornamento | UBS | Neutral → Buy |
| 2019-04-18 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2019-01-25 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-26 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2018-07-02 | Iniziato | Goldman | Buy |
Mostra tutto
Resmed Inc Borsa (RMD) Ultime notizie
Geopolitics Watch: Is ResMed Inc Common Stock RMEA stock overpriced at current multiplesWeekly Profit Summary & Weekly Return Optimization Plans - moha.gov.vn
ResMed Inc Reports Changes in CHESS Depositary Interests and Securities - MSN
ResMed Inc. (NYSE:RMD) is favoured by institutional owners who hold 69% of the company - simplywall.st
ResMed Inc. $RMD Shares Sold by Inspire Investing LLC - MarketBeat
Here's What ResMed's (NYSE:RMD) Strong Returns On Capital Mean - Yahoo Finance
ResMed Inc. Reports Changes in Beneficial Ownership - MSN
The Truth About ResMed Inc: Is This Sleep Tech Stock Quietly Going Viral? - AD HOC NEWS
ResMed (RMD) Product Pipeline Analysis Report 2025 – ResearchAndMarkets.com - The AI Journal
ResMed (RMD) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Is ResMed CDI (ASX:RMD) Still Shaping Value For Investors? - Kalkine Media
Ethic Inc. Raises Stock Holdings in ResMed Inc. $RMD - MarketBeat
Is ResMed (RMD) a Solid Growth Stock? 3 Reasons to Think "Yes" - Yahoo Finance
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now? - The Globe and Mail
3 Stocks Likely to Gain From Rising HSA Contribution & Medicare Premium - TradingView — Track All Markets
ResMed Inc announces proposed sale of securities by director - MSN
The Truth About ResMed Inc.: Is This Sleep Tech Stock the Next Viral Gamechanger or Just Hype? - AD HOC NEWS
ResMed Stock Breathes Easier as Sleep-Apnea Giant Outpaces the Market - AD HOC NEWS
ResMed Inc. $RMD Stock Holdings Raised by Pacer Advisors Inc. - MarketBeat
Why analysts maintain buy rating on ResMed Inc. (RME) stockGlobal Market Influence & Big Gains Small Capital - bollywoodhelpline.com
ResMed Officer Plans Further Share Sale Under Rule 144 - MSN
ResMed Inc. (NYSE:RMD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Voya Investment Management LLC Has $8.97 Million Position in ResMed Inc. $RMD - MarketBeat
Swedbank AB Increases Stock Position in ResMed Inc. $RMD - MarketBeat
Is ResMed stock underperforming the S&P 500? - MSN
Why ResMed (RMD) is a Top Growth Stock for the Long-Term - Yahoo Finance
OLD National Bancorp IN Increases Stock Holdings in ResMed Inc. $RMD - MarketBeat
Patton Fund Management Inc. Has $265,000 Stock Holdings in ResMed Inc. $RMD - MarketBeat
Confluence Investment Management LLC Sells 4,405 Shares of ResMed Inc. $RMD - MarketBeat
Thrivent Financial for Lutherans Acquires 5,212 Shares of ResMed Inc. $RMD - MarketBeat
The Bull Case For ResMed (RMD) Could Change Following FDA-Cleared AI Smart Comfort CPAP Feature - Sahm
Texas Permanent School Fund Corp Sells 5,560 Shares of ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Sells 5,635 Shares of ResMed Inc. $RMD - MarketBeat
Will ResMed Inc. (Common Stock) (RMEA) stock beat revenue estimatesPortfolio Performance Report & Intraday High Probability Alerts - ulpravda.ru
Technical Analysis: Will ResMed Inc. stock gain from strong economyTrend Reversal & Weekly High Return Stock Forecasts - ulpravda.ru
Is ResMed Inc. stock attractive for long term wealth buildingJuly 2025 Price Swings & Real-Time Volume Analysis - DonanımHaber
Will ResMed Inc. stock deliver better than expected guidanceJuly 2025 Movers & Long Hold Capital Preservation Tips - DonanımHaber
Resmed Inc Officer Plans Sale of Common Stock - MSN
Will ResMed Inc. stock attract more institutional investorsMarket Volume Report & Real-Time Volume Triggers - Улправда
Will ResMed Inc. stock benefit from automationQuarterly Trade Review & Growth-Oriented Investment Plans - DonanımHaber
Why ResMed Inc. stock is a value investor pickJuly 2025 Short Interest & Smart Money Movement Tracker - Улправда
ResMed Inc. $RMD Shares Acquired by Addenda Capital Inc. - MarketBeat
Healthcare Equipment Focus as ResMed Appears in ASX 100 Landscape - Kalkine Media
Is ResMed Inc. stock in correction or buying zoneJuly 2025 Setups & Daily Technical Forecast Reports - Улправда
ResMed Inc. stock falls Thursday, underperforms market - MarketWatch
Resmed Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference - marketscreener.com
Two Resmed leaders take the J.P. Morgan Healthcare Conference stage - Stock Titan
ResMed (FRA:RMEA) EV-to-OCF : 17.84 (As of Dec. 18, 2025) - GuruFocus
Is It Too Late to Consider ResMed After Weight Loss Drug Concerns and DCF Outlook? - Sahm
Stifel Maintains ResMed (RMD) Hold Recommendation - Nasdaq
Will ResMed Inc. (RME) stock outperform Dow Jones2025 Momentum Check & Community Trade Idea Sharing Platform - Улправда
Stifel Nicolaus Adjusts ResMed Price Target to $260 From $270, Maintains Hold Rating - marketscreener.com
Resmed Inc Azioni (RMD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.54%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):